期刊
JOURNAL OF HEPATOLOGY
卷 65, 期 1, 页码 182-199出版社
ELSEVIER
DOI: 10.1016/j.jhep.2016.02.025
关键词
Human induced pluripotent stem cells (hiPSCs); Directed differentiation; Disease modelling; Drug screening; Toxicology studies; Regenerative medicine; Genomic integrity
资金
- European Commission [278152]
- French National Research Agency (ANR) [2010-RFCS-004, ANR-14-CE16-0026]
- Association Francaise contre les Myopathies [AFM DtT2 2012-16016]
- Region Ile de France (DIM Biotherapies)
- InnovaLiv grant
- StemHepTher grant
- Association Francaise contre les Myopathies (AFM)
- Agence Nationale de la Recherche (ANR) [ANR-14-CE16-0026] Funding Source: Agence Nationale de la Recherche (ANR)
Orthotopic liver transplantation remains the only curative treatment for liver disease. However, the number of patients who die while on the waiting list (15%) has increased in recent years as a result of severe organ shortages; furthermore the incidence of liver disease is increasing worldwide. Clinical trials involving hepatocyte transplantation have provided encouraging results. However, transplanted cell function appears to often decline after several months, necessitating liver transplantation. The precise aetiology of the loss of cell function is not clear, but poor engraftment and immune-mediated loss appear to be important factors. Also, primary human hepatocytes (PHH) are not readily available, de-differentiate, and die rapidly in culture. Hepatocytes are available from other sources, such as tumour-derived human hepatocyte cell lines and immortalised human hepatocyte cell lines or porcine hepatocytes. However, all these cells suffer from various limitations such as reduced or differences in functions or risk of zoonotic infections. Due to their significant potential, one possible inexhaustible source of hepatocytes is through the directed differentiation of human induced pluripotent stem cells (hiPSCs). This review will discuss the potential applications and existing limitations of hiPSCderived hepatocytes in regenerative medicine, drug screening, in vitro disease modelling and bioartificial livers. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据